Literature DB >> 31337589

[Update in the pharmacological treatment of neuropathic pain].

A Alcántara Montero1, P J Ibor Vidal2, A Alonso Verdugo3, E Trillo Calvo4.   

Abstract

We provide an updated review of the pharmacological treatment of neuropathic pain, with emphasis on the latest evidence-based recommendations. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin-noradrenaline reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second-line treatments include 5% lidocaine medicated plasters and capsaicin 8% patches, only for peripheral neuropathic pain and tramadol; whereas potent opioids and botulinum toxin A (for peripheral neuropathic pain) are considered third-line treatments. Future perspectives include the development of new drugs and a more personalised therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain.
Copyright © 2019 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Dolor neuropático; Emerging therapies; Farmacoterapia; Medicina personalizada; Neuropathic pain; Personalised medicine; Pharmacotherapy; Recomendaciones; Recommendations; Terapias emergentes

Mesh:

Year:  2019        PMID: 31337589     DOI: 10.1016/j.semerg.2019.05.008

Source DB:  PubMed          Journal:  Semergen        ISSN: 1138-3593


  2 in total

Review 1.  Defensive and Emotional Behavior Modulation by Serotonin in the Periaqueductal Gray.

Authors:  Priscila Vázquez-León; Abraham Miranda-Páez; Kenji Valencia-Flores; Hugo Sánchez-Castillo
Journal:  Cell Mol Neurobiol       Date:  2022-07-28       Impact factor: 4.231

2.  Depression and COVID-19 patients with chronic pain: practical considerations.

Authors:  A Alcántara Montero; S R Pacheco de Vasconcelos; F Peñato Tarifa
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2021-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.